Fig 1: Tat physically associates with SMYD5 and stabilizes SMYD5(A) SMYD5 co-immunoprecipitates with Tat. Cellular extracts from HEK293T cells expressing V5-SMYD5 or empty vector, alone or together with FLAG-Tat, were prepared 48 h after transfection and subjected to purification with anti-M2 FLAG affinity gel. The eluates were resolved by SDS-PAGE and subjected to western blotting.(B) Tat co-immunoprecipitates with SMYD5. Cellular extracts from HEK293T cells expressing V5-SMYD5 or empty vector, alone or together with FLAG-Tat, were prepared 48 h after transfection and subjected to purification with anti-V5 affinity gel. The eluates were resolved by SDS-PAGE and subjected to western blotting.(C) Tat increases SMYD5 protein expression. HEK293T cells were transfected with 500 ng V5-SMYD5 and 0–200 ng of FLAG-Tat or 0–200 ng FLAG-GFP plasmids. After 48 h, cells were lysed and subjected to western blot analysis.(D and E) TNF-a increases SMYD5-Tat co-immunoprecipitation but not SMYD5 RNA production. J-Lat 5A8 cells were treated with increasing amounts of TNF-a. After 48 h, cells were lysed in FLAG-IP buffer and subjected to western blot analysis (C) or lysed in RLT+ buffer to isolate mRNA (QIAGEN) (D). RNA levels were analyzed by qRT-PCR and normalized to RPL13A RNA. All IPs, western blots, and qPCRs were repeated at least three times. Representative results of IPs and western blots are shown. qPCR results of three biological replicates (±SEM) are shown.
Fig 2: SMYD5 and Tat interact with USP11(A) Network representation of the interactions of HIV-1 Tat with human proteins,36 highlighting USP11.(B) Endogenous USP11 co-immunoprecipitates with FLAG-Tat. HEK293T cells were transfected with 200 ng of FLAG-Tat WT, FLAG-GFP, or empty vector. After 48 h cells were lysed in FLAG IP buffer and subjected to FLAG IP and Western blot analysis of endogenous USP11. Note that we consider the lower band in the blot nonspecific because it is not downregulated in (D).(C) Tat and endogenous USP11 co-immunoprecipitate with V5-SMYD5. HEK293T cells were transfected with plasmids expressing V5-SMYD5 or empty vector, alone or together with FLAG-Tat. After 48 h, cells were lysed in FLAG IP buffer and subjected to V5 immunoprecipitation and western blot analysis. All IPs and western blots were repeated at least three times. Representative results of IPs and western blots are shown.(D) USP11 knockdown inhibits Tat-mediated SMYD5 stabilization. HeLa cells were transduced with lentiviral vectors expressing shRNA targeting USP11 or a non-targeting control and selected by puromycin treatment. Successfully transduced cells were transfected with increasing amounts of Tat and, after 48 h, subjected to western blot analysis. Note that we consider the lower band in the blot nonspecific.(E) Quantification of 3 independent experiments/western blots of SMYD5 bands in (D) by densitometric analyses using ImageJ. Each V5-SMYD5 band from shUSP11 was compared with its corresponding control-treated band (for example, 1 ng Tat control vs. 1 ng Tat shUSP11). Data are represented as means plus SEM.
Fig 3: SMYD5 knockdown inhibits HIV-1 reactivation from latency in J-Lat cells(A) Schematic of the workflow. J-Lat 5A8 cells were transduced with SMYD5 shRNA, puromycin selected, and activated with aCD3/CD28 antibodies for 18 h, and GFP+ cells were analyzed by flow cytometry.(B) SMYD5 protein levels in J-Lat 5A8 cells after targeting its RNA with two different lentiviral shRNAs or a non-targeting control.(C) Reactivation of the latent HIV-1 reporter as measured by GFP flow cytometry. Both SMYD5 shRNAs suppress HIV-1 reactivation under basal conditions and upon activation with aCD3/CD28. The average of three independent experiments analyzed in triplicate ±SEM is shown and compared with control samples by ANOVA: **p < 0.005, ***p < 0.001.(D) Cell viability (percentage of live cells), as monitored by forward and side scatter analysis and viability stain, under the same conditions as in (C). The average ofthree independent experiments analyzed in triplicate ± SEM is shown.(E) J-Lat 5A8 cells were transduced with SMYD5 shRNA, puromycin selected for 3 days, and infected a second time with VSV-G pseudotyped virus containing aSMYD5 expression plasmid. After 72 h and 96 h, GFP+ cells were analyzed by flow cytometry. SMYD5 overexpression restores HIV-1 reactivation in SMYD5 knockdown cells under basal conditions. The average of three independent experiments analyzed in triplicate ±SEM is shown and compared with control samples by ANOVA: **p < 0.005.
Fig 4: SMYD5 is expressed and upregulated upon activation in primary CD4+ T cells, and its knockdown inhibits HIV-1 expression(A) SMYD5 protein and mRNA expression in CD4+ T cells from the blood of two independent human donors. The cells were treated with 20 ng/mL TNF-a or aCD3/CD28 Dynabeads (1 bead per 2 cells) for 24 h, then lysed in FLAG immunoprecipitation (IP) buffer for western blot analysis or in RLT+ lysis buffer to isolate mRNA (QIAGEN). RNA levels were analyzed by qRT-PCR and normalized to RPL13A RNA. The average (mean ± SEM) from triplicate experiments performed with two different donors is shown.(B) shRNA-mediated knockdown of SMYD5 in CD4+ T cells. Shown is a schematic of the workflow. Primary CD4+ T cells isolated from uninfected blood donors were activated with aCD3/CD28 Dynabeads for 3 days, infected first with lentiviral particles encoding shRNA against SMYD5 or a non-targeting control, and second with a GFP-tagged reporter virus in the background of HIVNL4–3.(C–E) Impact of non-targeting or SMYD5-targeting shRNAs on the percentage of HIV-1 expressing (GFP+) cells (C), the percentage of live cells as measured by forward scatter analysis and viability stain (D), and the level of SMYD5 mRNA as determined by RT-PCR normalized to RPL13A mRNA (E) among activated CD4+ T cells from three independent donors. The average (mean ± SEM) from triplicate experiments performed with three different donors is shown.
Fig 5: Model of SMYD5’s activator function at the HIV-1 LTRSMYD5 can activate the HIV-1 LTR alone through its intrinsic TAR RNA-binding capacity and in conjunction with Tat.
Supplier Page from DNASU for SMYD5 (Homo sapiens) in pLenti6.2/V5-DEST (V5-tagged lentiviral mammalian expression vector)